Sandoz Completes Deal For Mycamine

Acquisition Of Antifungal Brand From Astellas Was Announced In Early 2023

 
• By Dave Wallace

Just weeks before Sandoz completes its separation from parent firm Novartis, the company has completed a deal for worldwide rights to the Mycamine antifungal brand from Astellas.

Company sign reading Sandoz A Novartis Division
Sandoz has completed its deal for rights to Mycamine • Source: Shutterstock

More from Deals

More from Business